Aliskiren 150 mg

DRUG4 trials

Sponsors

Novartis, Novartis Pharmaceuticals, Vanderbilt University Medical Center

Conditions

Essential HypertensionHeart FailureHigh Blood PressureHypertension

Phase 2

A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure

CompletedNCT01125514

Novartis PharmaceuticalsHeart Failure

Start: 2010-05-31End: 2011-08-31Updated: 2012-09-10

Phase 3

Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study

CompletedNCT00706134

NovartisHypertension

Start: 2008-05-31End: 2009-04-30Updated: 2011-06-28

Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

CompletedNCT01237223

NovartisEssential Hypertension

Start: 2010-10-31End: 2011-05-31Updated: 2012-06-13

Phase 4

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function

CompletedNCT03115853

Vanderbilt University Medical CenterHigh Blood Pressure

Start: 2009-06-30End: 2012-01-31Updated: 2017-08-25